Free Trial
NYSE:OSTX

OS Therapies (OSTX) Stock Price, News & Analysis

OS Therapies logo
$1.76 -0.02 (-1.18%)
As of 03:51 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About OS Therapies Stock (NYSE:OSTX)

Key Stats

Today's Range
$1.67
$1.77
50-Day Range
$1.53
$1.98
52-Week Range
$1.12
$7.00
Volume
274,239 shs
Average Volume
736,515 shs
Market Capitalization
$49.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

OS Therapies Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

OSTX MarketRank™: 

OS Therapies scored higher than 41% of companies evaluated by MarketBeat, and ranked 692nd out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OS Therapies has received a consensus rating of Buy. The company's average rating score is 3.40, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    OS Therapies has only been the subject of 1 research reports in the past 90 days.

  • Read more about OS Therapies' stock forecast and price target.
  • Earnings Growth

    Earnings for OS Therapies are expected to grow in the coming year, from ($0.64) to ($0.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OS Therapies is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OS Therapies is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for OSTX.
  • Dividend Yield

    OS Therapies does not currently pay a dividend.

  • Dividend Growth

    OS Therapies does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OSTX.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for OS Therapies this week, compared to 2 articles on an average week.
  • Search Interest

    19 people have searched for OSTX on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.
  • MarketBeat Follows

    14 people have added OS Therapies to their MarketBeat watchlist in the last 30 days. This is an increase of 180% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OS Therapies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,000.00 in company stock.

  • Percentage Held by Insiders

    13.80% of the stock of OS Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about OS Therapies' insider trading history.
Receive OSTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OS Therapies and its competitors with MarketBeat's FREE daily newsletter.

OSTX Stock News Headlines

Head to Head Contrast: OS Therapies (OSTX) and The Competition
One stock to replace Nvidia
I'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce competitors, dethroning the AI Chip King. But there's a critical component that AI data centers need just as badly as chips. The demand is so massive that a single data center uses enough of it to stretch around the earth eight times. While the media hypes up AI chips, the smart money has found the next big thing. Discover Futurist Eric Fry's "Nvidia-killer" stock ideas.
OS Therapies Inc News (OSTX) - Investing.com
See More Headlines

OSTX Stock Analysis - Frequently Asked Questions

OS Therapies' stock was trading at $4.28 at the beginning of 2025. Since then, OSTX shares have decreased by 59.2% and is now trading at $1.7450.

OS Therapies (OSTX) raised $8 million in an initial public offering on Thursday, August 1st 2024. The company issued 2,000,000 shares at $4.00 per share. Brookline Capital Markets (Division of Arcadia Securities LLC) served as the underwriter for the IPO.

Shares of OSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that OS Therapies investors own include AST SpaceMobile (ASTS), Energy Transfer (ET), Black Stone Minerals (BSM), Kinder Morgan (KMI), Main Street Capital (MAIN), Atlas Energy Solutions (AESI) and Chevron (CVX).

Company Calendar

Today
8/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:OSTX
Previous Symbol
NYSE:OSTX
CIK
1795091
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

High Price Target
$20.00
Low Price Target
$15.00
Potential Upside/Downside
+911.2%
Consensus Rating
Buy
Rating Score (0-4)
3.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.86)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-569.57%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.76
Quick Ratio
0.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
28,098,000
Free Float
N/A
Market Cap
$50.01 million
Optionable
N/A
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NYSE:OSTX) was last updated on 8/1/2025 by MarketBeat.com Staff
From Our Partners